EVR 6.7MSFT 0.71DAL 0.73JPM 10.04ATD.TO 0.76MTD 11.16CRWD -28.52
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.69
+0.35 (1.38%)
as of Jun 4, 2026, 8:00:00 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing significant challenges, primarily due to a patent cliff and a lack of earnings momentum following the COVID-19 pandemic. Many experts express concerns over its drug pipeline, indicating that the company is in need of a blockbuster drug to drive future growth. While it maintains an attractive dividend yield—ranging from 6.4% to 7%—there is skepticism about the sustainability of this yield if new profitable drugs are not developed soon. The stock’s valuation is seen as low, trading at around 8-10 times earnings, which some experts believe might make it appealing for patient investors. However, the consensus also points to caution due to the industry-wide challenges, including cost-cutting measures and potential government pressure on drug pricing.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
DON'T BUY

Pfizer Inc(PFE)

Aug 21, 2008
Pharmaceutical group is behaving better. This one is less attractive and is facing drugs coming off patent. Prefers others.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$19.37

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 06, 2008
Earnings where fantastic. Yield of 6.6%.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$19.43

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jul 16, 2008
At an interesting Buy point but not sure he would buy it currently. On his Watch list.
Photo of Peter BriegerPeter Brieger
No
Unlock Rating
$18.26

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jul 11, 2008
(Market Call Minute.) Broken stock and he can't see what is going to turn it around.
Photo of David BurrowsDavid BurrowsUnlock Rating
$17.81

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jul 10, 2008
All of the big pharma have been very disappointing. Now yielding over 7% but doesn't think the dividend is in jeopardy as the cash flow is amazingly strong. Won't be a great investment for another year or so.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$18.03

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 04, 2008
Not cheap enough for him yet. He would have to go over the financial statements. There are a lot of companies in this area that may be of interest in the next few years.
Photo of Benj GallanderBenj Gallander
No
Unlock Rating
$17.75

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 11, 2008
Model price has been decreasing over the last 9 months, but not all that much. Thinks it will go down to $15.75 but he sees in setting up as a huge rally in healthcare related stocks in Q4 or Q1 of 09. Has an 86% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$17.55

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 10, 2008
Pharmaceutical industry in the US has been a disappointment for 2 or 3 years. There is concern about the new drug pipeline. Also a large number of blockbuster drugs are coming off patent for many companies. Also increased competition from generic companies. At 7.2%, the market is telling you it does not believe the dividend is safe.
Photo of David BaskinDavid BaskinUnlock Rating
$17.94

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 09, 2008
Its problem, along with many of the health care companies in the US, is the pipeline. Lipitor, which is a large portion of their revenues, comes off patent next year. Have lots of cash flow but haven't been able to take advantage to develop anything. Would buy Novo-Nordisk (NVO-N) instead.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$18.02

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 05, 2008
From his perspective, it has absolutely technically broken down. Looks like almost everything is going against it. Also, it is likely Democrats will come to power and won't be helpful to the drug companies.
Photo of Ross HealyRoss Healy
No
Unlock Rating
$18.67

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jun 03, 2008
6.73% dividend. Doesn't see a lot of prospects in their pipeline. Some of their big money makers are in a lot of jeopardy from competition. If you like pharmaceuticals, consider moving into Johnson & Johnson (JNJ-N).
Photo of Duncan StewartDuncan Stewart
No
Unlock Rating
$19.01

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jun 02, 2008
Product portfolio continues to undergo greater competition from generics. New products are declining. Still haven't turned the corner. Generics such as Teva Pharmaceutical (TEVA-Q) would be more attractive.
Photo of David GarrityDavid Garrity
No
Unlock Rating
$19.18

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 21, 2008
Candidates in the presidential race have not been positive on pharmaceutical companies. The problem with this company however is the lack of a pipeline. Most of the earnings are coming from some products that are going to go off patent in the next couple of years. Has become more and more expensive to generate new drugs. The dividend could be a potential trap and could be lowered.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$20.01

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

May 15, 2008
6.5% dividend yield. Cash flows are very strong.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$20.08

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 14, 2008
Recently sold his holdings. A lot of their pipeline is going into generic distribution, which will take a lot of revenue off the top line. Feels the 6% dividend is probably safe.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$20.06

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 511 to 525 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO 5.13$270.94
BHP -2.07$88.78
TA.TO -2.08$18
V 7.78$320.18
TOU.TO -0.12$65.42

Today's Top Picks

EVR 6.7$346.79
MSFT 0.71$428.05
DAL 0.73$79.51
JPM 10.04$310.89
ATD.TO 0.76$80.79

Popular Articles

Latest Sell Signals

PRL.TO 0.07$21.2
CNQ.TO -0.14$66.22
SHOP.TO 4.46$161.54
RIO -2.46$105.4
BB.TO 0.3$14.4

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica